Project: Novel therapeutic mimotope-AAVLP cancer vaccine engineered using NGS-guided molecular evolution
| Acronym | MimoVac-E (Reference Number: 12406) |
| Duration | 30/09/2018 |
| Project Topic | We will develop a vaccine that mobilizes the patient’s immune system for a potent and long-lasting response against cancer cells in head and neck cancer (HNC), where there is a major unmet medical need. Based on a clinically approved monoclonal antibody, we will develop novel cancer mimotopes displayed numerously on adeno-associated virus-like particles (AAVLP). The vaccine is validated in vitro and preclinically during the project, and successively continued into a clinical phase I study. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 9 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | 2A Pharma AB | Coordinator | Sweden |
| 2 | DNASense ApS | Partner | Denmark |
| 3 | Danish Technological Institute | Partner | Denmark |